We want to hear from you. Complete a feedback survey here or leave a comment on the app's iTunes or Google Play page.

Use the updated AnticoagEvaluator to make informed decisions on initiation of antithrombotic therapy for patients with clinical atrial fibrillation (AF) who do not have moderate to severe mitral stenosis or a mechanical heart valve. App updates include expanded advice from the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.

Use the app to:

• Calculate a patient's stroke risk (CHA₂DS₂-VASc, ATRIA, and GARFIELD-AF) and renal function (Cockcroft-Gault Equation), and review factors that may contribute to bleed risk (HAS-BLED criteria and concomitant meds).
• Calculate a patient's mortality risk (GARFIELD-AF).
• Consider updated stroke prevention therapy guidance based on the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.
• Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics.
• Evaluate appropriate therapy for a patient by reviewing:
  • Synthesized individualized risk for antithrombotic therapy options based on clinical trials (e.g., ACTIVE-A, RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE-AF).
  • Relevant safety information and full prescribing information for all therapy options.

If you already have the app downloaded on your mobile device, simply update the app the same way that you receive updates for any other app. To download the app for the first time, search for the name of the app in the iTunes or Google Play app store, or use the below links.

Download the App From iTunes >>> Download the App From Google Play >>> Launch the Web Version >>>

Information in the updated app was derived from the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. The information and recommendations in this app are intended to support clinical decision making. They are not intended to represent the only or best course of care, or to replace clinical judgment for diagnosis, cure, mitigation, treatment or prevention of disease. Use of this app assumes clinicians will conduct a full evaluation of the patient, consult relevant medical specialists as needed, and utilize a team-based approach to optimize therapy. In addition, therapeutic options should be determined after discussion between the patient and their care provider.

The app was developed as part of the ongoing mission of the ACC to generate and deliver actionable knowledge at the point of care to improve quality, efficiency and patient outcomes. This app was originally developed as part of the ACC's Anticoagulation Initiative, a comprehensive quality effort to improve care for patients on anticoagulation therapy. Financial support for the development of the app was provided by Daiichi Sankyo, Inc. All content was independently developed with no sponsor involvement. Therapy-adjusted risk magnitude calculations for CHA2DS2-VASc and HAS-BLED was adapted from a web tool created by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at http://www.sparctool.com/. The app was further refined and vetted through review and user testing by physicians, nurse practitioners, pharmacists, and other relevant specialists.

Questions?

Learn more about the app by reviewing a list of Frequently Asked Questions.

App Screenshots